SCHEMBL3532952

SCHEMBL3532952

CC(C)COC(=O)NC1CCN(c2cncc(-c3ccccc3O)n2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.43
CKS1B P61024 6/20 0.42
SKP1 P63208 6/20 0.42
SKP2 Q13309 6/20 0.42
HTR1A P08908 1/20 0.42
HTR2A P28223 1/20 0.42
CNR1 P21554 2/20 0.39
CNR2 P34972 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PDE10A Q9Y233 1/20 0.37
SMO Q99835 1/20 0.36
HSD11B1 P28845 1/20 0.36
THRB P10828 1/20 0.36
TSHR P16473 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PDCD1 Q15116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12991483 0.91 DRD2 (0.42) DRD2CKS1BSKP1SKP2HTR1A
SCHEMBL13037504 0.91 DRD2 (0.42) DRD2CKS1BSKP1SKP2HTR1A
SCHEMBL3537918 0.89 DRD2 (0.41) DRD2CKS1BSKP1SKP2HTR1A
SCHEMBL3533398 0.87 CNR1 (0.47) DRD2CKS1BSKP1SKP2HTR1A
SCHEMBL12991187 0.85 PDE10A (0.40) DRD2HTR1AHTR2APDE10AHSD11B1
SCHEMBL12991472 0.84 PDE10A (0.39) DRD2CKS1BSKP1SKP2HTR1A
SCHEMBL3528679 0.83 CKS1B (0.61) DRD2CKS1BSKP1SKP2CNR1
SCHEMBL3529359 0.82 DRD2 (0.42) DRD2CKS1BSKP1SKP2HTR1A
SCHEMBL12990835 0.82 HMOX1 (0.41) DRD2CKS1BSKP1SKP2ALDH1A1
SCHEMBL12990787 0.81 CNR1 (0.44) CKS1BSKP1SKP2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels KCNJ1, KCNJ2, KCNJ11 DRD2 3032/4885CKS1B 2173/4885SKP1 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.